The American multinational Carlyle Group buys UK pharmaceuticals Vectura Group for £958 million.
The chairman of Vectura group Bruno Angelici said:
“Vectura has made strong progress since embarking on its new strategy in 2019 to become a leading inhalation focused contract development and manufacturing organisation (CDMO), whilst continuing to deliver strong financial and operational results in its royalties and product supply businesses,”
He also mentioned that the directors of Vectura remains confident about the long term fundamentals of Vectura Group and the company believes that the current is an attractive offer for Vectura shareholders.
This offer also represents the strength, quality and long term performance of Vectura’s business and its future growth potential.
Because of Covid-19, the impact of the first quarter has been the same to the second half of 2020 with the revenues coming below.
About Carlyle Group
Carlyle is an American asset management, private equity and financial services corporation. It is one of the world’s largest and most diversified global investment firms, with assets worth $260 billion under management across three business segments and 437 investment vehicles.
According to PEI 300 index Carlyle was the world’s largest private equity firm by capital raised over the previous five years.
About Vectura Group
With more than Twenty years of experience Vectura Group is one among the leading Pharmaceuticals in United Kingdom, the company develops inhaled therapies for the treatment of respiratory diseases.
In the year the company acquired Innovata plc another developer of pulmonary products.
